Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548039 | 0.90 | CYP1A2 (0.50) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL12493846 | 0.86 | CYP1A2 (0.47) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL547624 | 0.85 | CYP1A2 (0.46) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL1715829 | 0.84 | CYP1A2 (0.53) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL14930772 | 0.83 | CYP1A2 (0.55) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL28036800 | 0.81 | GAA (0.47) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL5089500 | 0.81 | CYP1A2 (0.55) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL12494506 | 0.81 | CYP1A2 (0.55) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL11893308 | 0.80 | CYP1A2 (0.51) | CYP1A2GAACA12CA1CA2 | |
| SCHEMBL1715165 | 0.79 | CYP1A2 (0.57) | CYP1A2GAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013187-B1 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2014-10-29 | — | — | EP | claimed |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | claimed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | claimed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| EP-3106162-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | The Regents of the University of California (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2444085-A1 | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | The Regents of The University of California (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | CYP1A2 1469/4885GAA 4870/4885CA12 2570/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | CYP1A2 515/4885GAA 4863/4885CA12 1461/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | CYP1A2 2341/4885GAA 4869/4885CA12 793/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | CYP1A2 3479/4885GAA 4448/4885CA12 2918/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
| US-20130034501-A1 | DIARYLHYDANTOIN COMPOUNDS | FAP, LEF1, LPXN | CYP1A2 668/4885GAA 3990/4885CA12 392/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | CYP1A2 1177/4885GAA 4854/4885CA12 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.